Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)

    Summary
    EudraCT number
    2017-001773-17
    Trial protocol
    DE   ES   GB   BE   DK   IT  
    Global end of trial date
    20 Jun 2023

    Results information
    Results version number
    v2(current)
    This version publication date
    24 Aug 2024
    First version publication date
    29 Jun 2024
    Other versions
    v1
    Version creation reason

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    FGCL-4592-082
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03263091
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    FibroGen, Inc.
    Sponsor organisation address
    409 Illinois Street, San Francisco, United States, CA 94158
    Public contact
    Clinical Trial Information Desk, FibroGen, Inc., 082MDSstudy@fibrogen.com
    Scientific contact
    Clinical Trial Information Desk, FibroGen, Inc., 082MDSstudy@fibrogen.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Jun 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    20 Jun 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.
    Protection of trial subjects
    This study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), the International Council for Harmonisation (ICH) E6 Guidance for GCP, any other applicable local health and regulatory requirements and Institutional Ethics Committee (IEC) requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    29 Jan 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 11
    Country: Number of subjects enrolled
    Belgium: 4
    Country: Number of subjects enrolled
    Canada: 1
    Country: Number of subjects enrolled
    Denmark: 2
    Country: Number of subjects enrolled
    France: 7
    Country: Number of subjects enrolled
    Germany: 14
    Country: Number of subjects enrolled
    India: 7
    Country: Number of subjects enrolled
    Israel: 17
    Country: Number of subjects enrolled
    Italy: 10
    Country: Number of subjects enrolled
    Korea, Democratic People's Republic of: 15
    Country: Number of subjects enrolled
    Poland: 15
    Country: Number of subjects enrolled
    Russian Federation: 13
    Country: Number of subjects enrolled
    Spain: 21
    Country: Number of subjects enrolled
    Türkiye: 16
    Country: Number of subjects enrolled
    United Kingdom: 8
    Country: Number of subjects enrolled
    United States: 23
    Worldwide total number of subjects
    184
    EEA total number of subjects
    73
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    45
    From 65 to 84 years
    126
    85 years and over
    13

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study included 3 components: Open-label (OL) Lead-in, Double-blind (DB), and OL High-erythropoietin (High-EPO) component. Participants were enrolled in sequential dose level cohorts in OL lead-in component prior to the start of DB component.

    Pre-assignment
    Screening details
    Concurrent with enrollment in DB component, participants with high serum EPO levels (>400 milli-international units [mIU]/milliliter [mL]), exclusionary for DB component, were enrolled in an OL high-EPO component. Participants with lower-risk myelodysplastic syndrome (MDS) with LTB were randomized 3:2 to roxadustat or placebo in DB component.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg
    Arm description
    Participants received roxadustat 1.5 milligrams (mg)/kilograms (kg), three times a week (TIW) for 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Roxadustat
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Roxadustat was administered per schedule specified in the arm description.

    Arm title
    OL Component (Cohort 2): Roxadustat 2.0 mg/kg
    Arm description
    Participants received roxadustat 2.0 mg/kg, TIW for 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Roxadustat
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Roxadustat was administered per schedule specified in the arm description.

    Arm title
    OL Component (Cohort 3): Roxadustat 2.5 mg/kg
    Arm description
    Participants received roxadustat 2.5 mg/kg, TIW for 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Roxadustat
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Roxadustat was administered per schedule specified in the arm description.

    Arm title
    OL High-EPO Component: Roxadustat 2.5 mg/kg
    Arm description
    Participants with high serum EPO levels (>400 mIU/mL) received roxadustat 2.5 mg/kg TIW for 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Roxadustat
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Roxadustat was administered per schedule specified in the arm description.

    Arm title
    DB Component: Roxadustat
    Arm description
    Participants received roxadustat 2.5 mg/kg TIW for 52 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Roxadustat
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Roxadustat was administered per schedule specified in the arm description.

    Arm title
    DB Component: Placebo
    Arm description
    Participants received placebo matched to roxadustat for 52 weeks.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo matched to roxadustat was administered per schedule specified in the arm description.

    Number of subjects in period 1
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg DB Component: Roxadustat DB Component: Placebo
    Started
    8
    8
    8
    20
    82
    58
    Received at least 1 dose of study drug
    8
    8
    8
    20
    82
    58
    Completed
    6
    6
    6
    10
    38
    37
    Not completed
    2
    2
    2
    10
    44
    21
         Adverse event, serious fatal
    1
    -
    -
    3
    7
    4
         Consent withdrawn by subject
    1
    1
    -
    6
    22
    8
         Physician decision
    -
    1
    2
    1
    3
    1
         Adverse event, non-fatal
    -
    -
    -
    -
    2
    1
         Other than specified
    -
    -
    -
    -
    8
    6
         Lost to follow-up
    -
    -
    -
    -
    2
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg
    Reporting group description
    Participants received roxadustat 1.5 milligrams (mg)/kilograms (kg), three times a week (TIW) for 52 weeks.

    Reporting group title
    OL Component (Cohort 2): Roxadustat 2.0 mg/kg
    Reporting group description
    Participants received roxadustat 2.0 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL Component (Cohort 3): Roxadustat 2.5 mg/kg
    Reporting group description
    Participants received roxadustat 2.5 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL High-EPO Component: Roxadustat 2.5 mg/kg
    Reporting group description
    Participants with high serum EPO levels (>400 mIU/mL) received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Roxadustat
    Reporting group description
    Participants received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Placebo
    Reporting group description
    Participants received placebo matched to roxadustat for 52 weeks.

    Reporting group values
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg DB Component: Roxadustat DB Component: Placebo Total
    Number of subjects
    8 8 8 20 82 58 184
    Age Categorical
    Units: participants
        <65 Years
    3 0 2 8 18 14 45
        ≥65 Years
    5 8 6 12 64 44 139
    Sex: Female, Male
    Units: participants
        Female
    3 3 6 6 36 21 75
        Male
    5 5 2 14 46 37 109
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0 0 0 0 0
        Asian
    0 0 0 3 14 7 24
        Native Hawaiian or Other Pacific Islander
    0 0 0 0 0 0 0
        Black or African American
    0 0 0 0 0 0 0
        White
    7 8 8 17 63 49 152
        More than one race
    0 0 0 0 0 0 0
        Unknown or Not Reported
    1 0 0 0 5 2 8
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    1 1 0 1 1 2 6
        Not Hispanic or Latino
    7 7 6 19 78 55 172
        Unknown or Not Reported
    0 0 2 0 3 1 6

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg
    Reporting group description
    Participants received roxadustat 1.5 milligrams (mg)/kilograms (kg), three times a week (TIW) for 52 weeks.

    Reporting group title
    OL Component (Cohort 2): Roxadustat 2.0 mg/kg
    Reporting group description
    Participants received roxadustat 2.0 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL Component (Cohort 3): Roxadustat 2.5 mg/kg
    Reporting group description
    Participants received roxadustat 2.5 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL High-EPO Component: Roxadustat 2.5 mg/kg
    Reporting group description
    Participants with high serum EPO levels (>400 mIU/mL) received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Roxadustat
    Reporting group description
    Participants received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Placebo
    Reporting group description
    Participants received placebo matched to roxadustat for 52 weeks.

    Primary: OL and OL High-EPO Components: Number of Participants who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 weeks of Treatment

    Close Top of page
    End point title
    OL and OL High-EPO Components: Number of Participants who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 weeks of Treatment [1] [2]
    End point description
    The RBC TI was defined as the absence of any intravenous (IV) RBC transfusion (packed cell or whole blood) during any consecutive 56 days during the treatment period. Data presented is for number of participants with RBC TI ≥8 weeks (≥56 consecutive days) since first dose in the first 28 weeks of treatment. The full analysis set (FAS) included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment hemoglobin (Hb) assessment.
    End point type
    Primary
    End point timeframe
    28 weeks
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The end point is reporting statistics for the specified arms only.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg
    Number of subjects analysed
    8
    8
    8
    20
    Units: participants
    3
    1
    5
    3
    No statistical analyses for this end point

    Primary: DB Component: Number of Participants who Achieved RBC TI ≥56 Consecutive Days Since First Dose in the First 28 Weeks of Treatment

    Close Top of page
    End point title
    DB Component: Number of Participants who Achieved RBC TI ≥56 Consecutive Days Since First Dose in the First 28 Weeks of Treatment [3]
    End point description
    RBC TI was defined as the absence of any IV RBC transfusion (packed cell or whole blood) during any consecutive 56 days during the treatment period. Data presented is for number of participants with RBC TI ≥56 consecutive days since first dose in the first 28 weeks of treatment. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Primary
    End point timeframe
    28 weeks
    Notes
    [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: participants
    38
    19
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    The odds ratio along with its 95% confidence interval (CI) were calculated based on the Cochran-Mantel-Haenszel (CMH) chi-square test adjusting for the stratification factors (EPO level, International Prognostic Scoring System – Revised [IPSS-R] risk category and RBC transfusion burden).
    Comparison groups
    DB Component: Roxadustat v DB Component: Placebo
    Number of subjects included in analysis
    137
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.217
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    1.582
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.761
         upper limit
    3.29

    Secondary: OL and OL High-EPO Components: Number of Participants who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions over 8 Weeks

    Close Top of page
    End point title
    OL and OL High-EPO Components: Number of Participants who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions over 8 Weeks [4]
    End point description
    Number of pRBC transfusions at baseline was defined as pRBC transfusions requirement during 8-week period prior to the start of first study medication. Responders were defined as participants with at least a 50% reduction in the number of pRBC transfusions over any 8-week (56 consecutive days) period during the study as compared with the baseline. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 8
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg
    Number of subjects analysed
    8
    8
    8
    20
    Units: participants
    5
    3
    7
    8
    No statistical analyses for this end point

    Secondary: DB Component: Number of Participants who Achieved TI ≥56 Consecutive Days Since First Dose in 52 Weeks of Treatment

    Close Top of page
    End point title
    DB Component: Number of Participants who Achieved TI ≥56 Consecutive Days Since First Dose in 52 Weeks of Treatment [5]
    End point description
    RBC TI was defined as the absence of any IV RBC transfusion (packed cell or whole blood) during any consecutive 56 days during the treatment period. Data presented is for number of participants with RBC TI ≥56 consecutive days since first dose in the 52 weeks of treatment. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    52 weeks
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: participants
    44
    23
    No statistical analyses for this end point

    Secondary: DB Component: Number of Participants who Achieved TI ≥56 Consecutive Days Anytime During the Study

    Close Top of page
    End point title
    DB Component: Number of Participants who Achieved TI ≥56 Consecutive Days Anytime During the Study [6]
    End point description
    RBC TI was defined as the absence of any IV RBC transfusion (packed cell or whole blood) during any consecutive 56 days anytime during the study (up to Week 56). FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 56
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: participants
    52
    29
    No statistical analyses for this end point

    Secondary: DB Component: Number of Participants who Achieved ≥50% Reduction From Baseline in Number of pRBC Transfusions Over 8 Weeks

    Close Top of page
    End point title
    DB Component: Number of Participants who Achieved ≥50% Reduction From Baseline in Number of pRBC Transfusions Over 8 Weeks [7]
    End point description
    Baseline number of transfusions (pRBC/8-weeks) = total number of packs of rRBCs within 16 weeks prior to first dose/2. A pRBC transfusion reduction responder was defined as a participant who achieved ≥50% reduction in number of pRBC transfusions over 8 weeks compared to their baseline for any 8 week period in the duration begining with the first dose date (Day 1) and ending with the end of study or treatment discontinuation due to adverse event (AE)/serious adverse event (SAE) or death, whichever came earlier. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 8
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: participants
    59
    37
    No statistical analyses for this end point

    Secondary: DB Component: Cumulative Number of Participant Exposure Weeks (PEW) of TI Over the First 28 Weeks of Treatment

    Close Top of page
    End point title
    DB Component: Cumulative Number of Participant Exposure Weeks (PEW) of TI Over the First 28 Weeks of Treatment [8]
    End point description
    The PEW of TI periods over the first 28 weeks was added up to a cumulative number of weeks. For a participant with at least 1 TI response period over the first 28 weeks, the last TI response period was ended with the date of a subsequent RBC transfusion, visit date at Week 28, date of the end of study or treatment discontinuation due to AE/SAE or death, whichever came earlier. For a participant with no TI response period over the first 28 weeks, the cumulative number of PEW was set to zero. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    28 weeks
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: weeks
        arithmetic mean (standard deviation)
    9.60 ( 11.537 )
    7.60 ( 11.557 )
    No statistical analyses for this end point

    Secondary: DB Component: Change From Baseline in Number of pRBC Packs Transfused Over the First 28 Weeks of Treatment

    Close Top of page
    End point title
    DB Component: Change From Baseline in Number of pRBC Packs Transfused Over the First 28 Weeks of Treatment [9]
    End point description
    Number of pRBC transfusions at baseline was defined as pRBC transfusions requirement during 8-week period prior to the start of first study medication. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 28
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: pRBC packs
        arithmetic mean (standard deviation)
    -0.13 ( 2.314 )
    0.44 ( 1.833 )
    No statistical analyses for this end point

    Secondary: DB Component: Number of Participants who Achieved TI ≥20 Consecutive Weeks During the Study

    Close Top of page
    End point title
    DB Component: Number of Participants who Achieved TI ≥20 Consecutive Weeks During the Study [10]
    End point description
    ≥20 consecutive weeks TI was defined as the absence of any IV RBC transfusion (packed cell or whole blood) during any consecutive 140 days anytime during the study (up to 56 weeks). TI was estimated between the first dose date (Day 1) and the end of study (Week 56) or treatment discontinuation due to AE/SAE or death, whichever came earlier. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 56
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    80
    57
    Units: participants
    23
    15
    No statistical analyses for this end point

    Secondary: DB Component: Mean Change from Baseline in the Patient-Reported Outcomes Measurement Information System-Short Form (PROMIS-SF) v2.0 Physical Function (PF) 10b Score at Week 9

    Close Top of page
    End point title
    DB Component: Mean Change from Baseline in the Patient-Reported Outcomes Measurement Information System-Short Form (PROMIS-SF) v2.0 Physical Function (PF) 10b Score at Week 9 [11]
    End point description
    The PROMIS PF 10-item short form which contains 10 questions was used in this study, and each item was scored on a 5-point rating scale (1 [unable to do] to 5 [without any difficulty]), with higher scores indicating better functioning. Total raw score was the sum of the response to each question, with the lowest possible raw score 10 (poor physical function) and the highest possible raw score 50 (better physical function). Raw scores converted to T-scores (as detailed in the T-score conversion table for PROMIS-SF v2.0 Physical Function 10b) with a mean of 50 and a standard deviation (SD) of 10. T-scores ranged from minimum 13.8 to maximum 61.3 possible scores with higher scores indicating better physical functioning. FAS = all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 9
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    71
    52
    Units: T-score
        arithmetic mean (standard deviation)
    -1.9 ( 7.29 )
    -0.4 ( 6.77 )
    No statistical analyses for this end point

    Secondary: DB Component: Mean Change from Baseline in the PROMIS-SF v1.0 Fatigue 13a Score at Week 9

    Close Top of page
    End point title
    DB Component: Mean Change from Baseline in the PROMIS-SF v1.0 Fatigue 13a Score at Week 9 [12]
    End point description
    Fatigue was measured using 13-item fatigue scale of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, each item was scored on a 5-point rating scale ranging from 1 “not at all” to 5 “very much”, with lower scores indicating better functioning. Total raw score was the sum of response to each question, with the lowest possible raw score 13 (lowest level of fatigue) and the highest possible raw score 65 (highest level of fatigue), with lower scores indicating better functioning. Raw scores converted to T-scores (as detailed in the T-score conversion table for PROMIS-SF v1.0 Fatigue 13a) with a mean of 50 and a SD of 10. T-scores ranged from minimum 30.3 to maximum 83.5 possible scores with lower scores indicating better functioning. FAS = all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment. 'Overall number of participants analyzed' = participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 9
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    67
    52
    Units: T-score
        arithmetic mean (standard deviation)
    1.9 ( 7.61 )
    -0.6 ( 7.36 )
    No statistical analyses for this end point

    Secondary: DB Component: Mean Change from Baseline in the European Quality of Life Five Dimensional Five Level Health Questionnaire (EQ-5D-5L) Visual Analogue Scale Score at Week 9

    Close Top of page
    End point title
    DB Component: Mean Change from Baseline in the European Quality of Life Five Dimensional Five Level Health Questionnaire (EQ-5D-5L) Visual Analogue Scale Score at Week 9 [13]
    End point description
    The EQ-5D questionnaire is designed for self-completion by participants. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problem, moderate problems, severe problems, and unable to/extreme problems. The questionnaire also included a visual analogue scale, where the participant was asked to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state and 100 being the best imaginable health. FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 9
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The end point is reporting statistics for the specified arms only.
    End point values
    DB Component: Roxadustat DB Component: Placebo
    Number of subjects analysed
    71
    55
    Units: units on a scale
        arithmetic mean (standard deviation)
    -1.7 ( 20.31 )
    1.6 ( 16.18 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Baseline up to Week 56
    Adverse event reporting additional description
    The safety analysis set included all participants who received at least 1 dose of study drug.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg
    Reporting group description
    Participants received roxadustat 1.5 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL Component (Cohort 2): Roxadustat 2.0 mg/kg
    Reporting group description
    Participants received roxadustat 2.0 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL Component (Cohort 3): Roxadustat 2.5 mg/kg
    Reporting group description
    Participants received roxadustat 2.5 mg/kg, TIW for 52 weeks.

    Reporting group title
    OL High-EPO Component: Roxadustat 2.5 mg/kg
    Reporting group description
    Participants with high serum EPO levels (>400 mIU/mL) received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Roxadustat
    Reporting group description
    Participants received roxadustat 2.5 mg/kg TIW for 52 weeks.

    Reporting group title
    DB Component: Placebo
    Reporting group description
    Participants received placebo matched to roxadustat for 52 weeks.

    Serious adverse events
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg DB Component: Roxadustat DB Component: Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 8 (50.00%)
    3 / 8 (37.50%)
    1 / 8 (12.50%)
    6 / 20 (30.00%)
    22 / 82 (26.83%)
    10 / 58 (17.24%)
         number of deaths (all causes)
    1
    0
    0
    3
    7
    4
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Malignant neoplasm progression
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral neck fracture
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic fracture
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb injury
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Traumatic haemorrhage
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute left ventricular failure
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Transient ischaemic attack
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain oedema
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Splenomegaly
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic function abnormal
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperbilirubinaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Portal hypertension
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    3 / 58 (5.17%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ureteric stenosis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Cervical spinal stenosis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal osteoarthritis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    4 / 82 (4.88%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Campylobacter gastroenteritis
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    OL Component (Cohort 1): Roxadustat 1.5 mg/kg OL Component (Cohort 2): Roxadustat 2.0 mg/kg OL Component (Cohort 3): Roxadustat 2.5 mg/kg OL High-EPO Component: Roxadustat 2.5 mg/kg DB Component: Roxadustat DB Component: Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    7 / 8 (87.50%)
    8 / 8 (100.00%)
    6 / 8 (75.00%)
    15 / 20 (75.00%)
    68 / 82 (82.93%)
    46 / 58 (79.31%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acute myeloid leukaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    2 / 20 (10.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    2
    2
    0
    Basal cell carcinoma
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Sweat gland tumour
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Pituitary tumour benign
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Malignant neoplasm progression
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Vascular disorders
    Orthostatic hypotension
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    0
    1
    2
    Hypotension
         subjects affected / exposed
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    4 / 82 (4.88%)
    2 / 58 (3.45%)
         occurrences all number
    2
    0
    0
    0
    5
    2
    Pallor
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    4 / 20 (20.00%)
    11 / 82 (13.41%)
    7 / 58 (12.07%)
         occurrences all number
    0
    0
    2
    5
    11
    10
    Fatigue
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    2 / 20 (10.00%)
    15 / 82 (18.29%)
    6 / 58 (10.34%)
         occurrences all number
    0
    0
    0
    2
    18
    9
    General physical health deterioration
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    2
    0
    Generalised oedema
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Influenza like illness
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Malaise
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Non-cardiac chest pain
         subjects affected / exposed
    3 / 8 (37.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    3
    1
    0
    2
    0
    0
    Pyrexia
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    5 / 82 (6.10%)
    1 / 58 (1.72%)
         occurrences all number
    0
    2
    0
    0
    5
    1
    Oedema peripheral
         subjects affected / exposed
    2 / 8 (25.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    2 / 20 (10.00%)
    9 / 82 (10.98%)
    4 / 58 (6.90%)
         occurrences all number
    3
    2
    0
    2
    13
    4
    Immune system disorders
    Seasonal allergy
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea exertional
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    3 / 58 (5.17%)
         occurrences all number
    0
    1
    0
    1
    0
    3
    Dyspnoea
         subjects affected / exposed
    2 / 8 (25.00%)
    2 / 8 (25.00%)
    2 / 8 (25.00%)
    1 / 20 (5.00%)
    8 / 82 (9.76%)
    1 / 58 (1.72%)
         occurrences all number
    2
    2
    2
    1
    9
    1
    Cough
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 20 (5.00%)
    4 / 82 (4.88%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    1
    4
    1
    Epistaxis
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    2
    1
    0
    0
    0
    1
    Nasal congestion
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Hypoventilation
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Nasal inflammation
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Pleuritic pain
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Productive cough
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    0
    1
    0
    0
    0
    2
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    1
    0
    2
    0
    Depression
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    Insomnia
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    9 / 82 (10.98%)
    0 / 58 (0.00%)
         occurrences all number
    1
    1
    1
    0
    9
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    10 / 82 (12.20%)
    7 / 58 (12.07%)
         occurrences all number
    1
    0
    0
    4
    18
    9
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    3 / 20 (15.00%)
    8 / 82 (9.76%)
    4 / 58 (6.90%)
         occurrences all number
    1
    1
    0
    8
    19
    5
    Weight decreased
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    2 / 20 (10.00%)
    7 / 82 (8.54%)
    1 / 58 (1.72%)
         occurrences all number
    0
    1
    0
    2
    7
    1
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    4
    0
    0
    0
    0
    Blood creatinine increased
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    0
    1
    0
    1
    0
    2
    Blood bilirubin increased
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    6 / 82 (7.32%)
    1 / 58 (1.72%)
         occurrences all number
    1
    0
    0
    2
    7
    1
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    1
    1
    0
    0
    1
    Fall
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    2 / 58 (3.45%)
         occurrences all number
    1
    0
    0
    0
    1
    2
    Injury
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Nasal injury
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Post-traumatic pain
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Cardiac disorders
    Angina pectoris
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    3 / 82 (3.66%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    3
    0
    Cardiac failure chronic
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    Palpitations
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    2 / 58 (3.45%)
         occurrences all number
    1
    0
    4
    0
    3
    2
    Tachycardia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    2 / 8 (25.00%)
    1 / 20 (5.00%)
    7 / 82 (8.54%)
    4 / 58 (6.90%)
         occurrences all number
    0
    1
    3
    1
    9
    4
    Dizziness
         subjects affected / exposed
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    1 / 20 (5.00%)
    11 / 82 (13.41%)
    10 / 58 (17.24%)
         occurrences all number
    2
    0
    3
    1
    14
    12
    Hypoaesthesia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    3
    0
    Restless legs syndrome
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    2
    0
    Presyncope
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    1
    0
    0
    0
    0
    2
    Neuralgia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    Sciatica
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Haemorrhagic diathesis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Neutropenia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    2 / 82 (2.44%)
    4 / 58 (6.90%)
         occurrences all number
    0
    0
    0
    3
    4
    9
    Thrombocytopenia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    5 / 82 (6.10%)
    2 / 58 (3.45%)
         occurrences all number
    0
    0
    0
    1
    7
    2
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    0
    0
    0
    2
    0
    2
    Eye disorders
    Dry eye
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    Visual impairment
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    2
    0
    Abdominal pain
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    4 / 58 (6.90%)
         occurrences all number
    1
    1
    0
    0
    2
    5
    Abdominal distension
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    Constipation
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    3 / 20 (15.00%)
    11 / 82 (13.41%)
    1 / 58 (1.72%)
         occurrences all number
    1
    1
    0
    3
    20
    1
    Diarrhoea
         subjects affected / exposed
    2 / 8 (25.00%)
    3 / 8 (37.50%)
    1 / 8 (12.50%)
    2 / 20 (10.00%)
    6 / 82 (7.32%)
    9 / 58 (15.52%)
         occurrences all number
    2
    4
    1
    2
    7
    11
    Dry mouth
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    1
    0
    1
    1
    Dyspepsia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    4 / 82 (4.88%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    0
    1
    4
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Mouth haemorrhage
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Mouth ulceration
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    Vomiting
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    1 / 20 (5.00%)
    6 / 82 (7.32%)
    2 / 58 (3.45%)
         occurrences all number
    0
    4
    1
    4
    12
    2
    Nausea
         subjects affected / exposed
    2 / 8 (25.00%)
    1 / 8 (12.50%)
    2 / 8 (25.00%)
    1 / 20 (5.00%)
    19 / 82 (23.17%)
    7 / 58 (12.07%)
         occurrences all number
    3
    2
    4
    1
    23
    8
    Hepatobiliary disorders
    Gallbladder disorder
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Hepatic steatosis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Jaundice
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Lichen planus
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Madarosis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Pruritus
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    8 / 82 (9.76%)
    2 / 58 (3.45%)
         occurrences all number
    1
    1
    0
    0
    8
    2
    Rash
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    1
    0
    0
    0
    0
    2
    Trichodynia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    3 / 58 (5.17%)
         occurrences all number
    0
    0
    0
    0
    1
    4
    Chronic kidney disease
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Proteinuria
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Renal cyst
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    1 / 8 (12.50%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    1
    2
    0
    0
    2
    0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    1 / 20 (5.00%)
    2 / 82 (2.44%)
    2 / 58 (3.45%)
         occurrences all number
    0
    0
    2
    2
    3
    2
    Arthralgia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 20 (0.00%)
    5 / 82 (6.10%)
    5 / 58 (8.62%)
         occurrences all number
    0
    0
    2
    0
    6
    5
    Myalgia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    3 / 82 (3.66%)
    3 / 58 (5.17%)
         occurrences all number
    0
    0
    0
    0
    3
    4
    Muscle spasms
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    5 / 82 (6.10%)
    2 / 58 (3.45%)
         occurrences all number
    0
    2
    0
    1
    8
    3
    Muscle contracture
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Flank pain
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    Osteoarthritis
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Spinal osteoarthritis
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    Oligoarthritis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Infections and infestations
    Anal abscess
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Atypical pneumonia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    COVID-19
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    4 / 82 (4.88%)
    6 / 58 (10.34%)
         occurrences all number
    0
    0
    0
    0
    4
    6
    Bronchitis
         subjects affected / exposed
    1 / 8 (12.50%)
    2 / 8 (25.00%)
    2 / 8 (25.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    0 / 58 (0.00%)
         occurrences all number
    1
    4
    3
    0
    2
    0
    Gingivitis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Kidney infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    4 / 82 (4.88%)
    5 / 58 (8.62%)
         occurrences all number
    2
    0
    1
    0
    4
    5
    Onychomycosis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Oral candidiasis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Pharyngitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Pneumonia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    3 / 58 (5.17%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    Respiratory tract infection
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Tonsillitis
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    0 / 58 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Sinusitis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    2 / 58 (3.45%)
         occurrences all number
    1
    0
    0
    0
    0
    2
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    5 / 58 (8.62%)
         occurrences all number
    0
    0
    2
    0
    3
    7
    Urinary tract infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    2 / 20 (10.00%)
    2 / 82 (2.44%)
    2 / 58 (3.45%)
         occurrences all number
    0
    0
    1
    4
    2
    3
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    6 / 82 (7.32%)
    5 / 58 (8.62%)
         occurrences all number
    1
    0
    0
    0
    10
    7
    Folate deficiency
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    4 / 82 (4.88%)
    4 / 58 (6.90%)
         occurrences all number
    0
    2
    0
    0
    4
    5
    Hyperglycaemia
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    2 / 20 (10.00%)
    2 / 82 (2.44%)
    1 / 58 (1.72%)
         occurrences all number
    1
    1
    1
    3
    2
    1
    Hyperkalaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 20 (5.00%)
    1 / 82 (1.22%)
    1 / 58 (1.72%)
         occurrences all number
    0
    0
    0
    2
    1
    1
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    0 / 82 (0.00%)
    1 / 58 (1.72%)
         occurrences all number
    0
    1
    0
    0
    0
    2
    Hypocalcaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    2 / 82 (2.44%)
    2 / 58 (3.45%)
         occurrences all number
    0
    1
    0
    0
    2
    2
    Hypomagnesaemia
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    1 / 58 (1.72%)
         occurrences all number
    0
    2
    0
    0
    1
    1
    Type 2 diabetes mellitus
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 20 (0.00%)
    1 / 82 (1.22%)
    0 / 58 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    16 May 2018
    It included following changes: - Added the following sections for additional clarity and details: Blinding; Maintenance of Blinding; Planned and Unplanned Unblinding of Treatment Assignment. - Change in enrollment criteria for greater flexibility in participant enrollment. - Added 4 Weeks Post-end of treatment (EOT). - Added If Early Termination, every 8 weeks assessment from 4 Weeks Post-EOT visit. Last visit at Week 52 from first dose. - Added Point-of-care Urine Pregnancy (for females of child-bearing capabilities).
    30 Jan 2020
    It included following changes: - Added a new open-label exploratory cohort: Open-label High-erythropoietin Component. - Exclusion criteria updated to: Participants with elevated serum erythropoietin levels (>400 mIU/mL) at Screening 1 are allowed to repeat after ≥ 7 days. If the serum erythropoietin remains elevated (>400 mIU/mL) the participant may then qualify for the OL High-erythropoietin cohort. - Exclusion criteria updated to: Participants with TBili up to 2.0 x upper limit of normal (ULN) may be allowed to participate if the sspartate aminotransferase (AST) and alanine aminotransferase (ALT) are within normal limits. - Following has been inserted as a secondary efficacy endpoint: Proportion of participants achieved TI ≥56 consecutive days at any time during the study. - Study centers planned has been revised to “Approximately 100”. -

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Study did not meet its primary efficacy endpoint; hence, the study was terminated early.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:03:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA